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Abstract: 
 
Recurrent epidemics of drug-resistant Staphylococcus aureus illustrate the rapid lapse of 
antibiotic efficacy following clinical implementation. Over the last decade, community-
associated methicillin-resistant S. aureus (MRSA) has emerged as a dominant cause of 
infections, and this problem is amplified by the hyper-virulent nature of these isolates. Herein, 
we report the discovery of a fungal metabolite, apicidin, as an innovative means to counter both 
resistance and virulence. Owing to its breadth and specificity as a quorum-sensing inhibitor, 
apicidin antagonizes all MRSA agr systems in a non-biocidal manner. In skin challenge 
experiments, the apicidin-mediated abatement of MRSA pathogenesis corresponds with quorum-
sensing inhibition at in vivo sites of infection. Additionally, we show that apicidin attenuates 
MRSA-induced disease by potentiating innate effector responses, particularly through 
enhanced neutrophil accumulation and function at cutaneous challenge sites. Together, these 
results indicate that apicidin treatment represents a strategy to limit MRSA virulence and 
promote host defense. 
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Recurrent epidemics of drug-resistant Staphylo-
coccus aureus illustrate the rapid lapse of antibiotic
efficacy following clinical implementation. Over the
last decade, community-associated methicillin-
resistant S. aureus (MRSA) has emerged as a domi-
nant cause of infections, and this problem is
amplified by the hyper-virulent nature of these iso-
lates. Herein, we report the discovery of a fungal
metabolite, apicidin, as an innovative means to
counter both resistance and virulence. Owing to its
breadth and specificity as a quorum-sensing inhibi-
tor, apicidin antagonizes all MRSA agr systems in a
non-biocidal manner. In skin challenge experiments,
the apicidin-mediated abatement of MRSA patho-
genesis corresponds with quorum-sensing inhibition
at in vivo sites of infection. Additionally, we show
that apicidin attenuates MRSA-induced disease by
potentiating innate effector responses, particularly
through enhanced neutrophil accumulation and
function at cutaneous challenge sites. Together,
these results indicate that apicidin treatment repre-
sents a strategy to limit MRSA virulence and promote
host defense.INTRODUCTION
Antibiotic-resistant pathogens threaten human health and eco-
nomic stability on a global scale (Laxminarayan et al., 2013;
Medina and Pieper, 2016). A common theme among recent re-
ports from the World Health Organization, US Centers for Dis-
ease Control and Prevention, the European Centre for Disease
Prevention and Control, the NIH, and theWorld Economic Forum
is that the post-antibiotic era looms ever closer as the loss of
efficacy among available antibiotics is far outpacing the genera-This is an open access article under the CC BY-Ntion of effective replacements (CDC, 2013; NIAID, 2014; O’Neill,
2016; Spellberg et al., 2016). Failure to reverse these trends
could lead to an exhaustion of protective interventions against
top pathogens. According to the Review on Antimicrobial Resis-
tance, infectious diseases are poised to claim 10 million lives per
year and account for 100 trillion dollars of lost economic output
by 2050 (O’Neill, 2016). Clearly, the growing specter of antibiotic
resistance warrants a reevaluation of long-term infection control
strategies for prominent pathogens.
While the pursuit of new antibiotics is a global heath impera-
tive, there is justifiable concern over a research and development
enterprise that is narrowly focused upon antibiotic discovery.
Given that the efficacy among clinically approved antibiotics is
achieved via bacteriostatic or bactericidal mechanisms, exten-
sive use of any given antibiotic therapy will eventually yield
resistant populations that emerge as a source of infection (Lax-
minarayan et al., 2013; Medina and Pieper, 2016). A circumspect
approach to infectious disease management mandates the
exploration of therapeutic alternatives that are devised to alle-
viate the selective pressure imposed by antibiotics (Laxminar-
ayan et al., 2013;Medina and Pieper, 2016). Providing a rationale
to advance the latter effort, the virulence attributes of many clin-
ically relevant pathogens are regulated through physiological
pathways that can be inhibited or ablated without cytotoxic ef-
fects. In this way, so-called anti-virulence therapies provide a
means of attenuating infectious illness without spurring evolution
toward a resistant phenotype (Cegelski et al., 2008; Laxminar-
ayan et al., 2013; Rasko and Sperandio, 2010). Therapeutic
targeting of quorum sensing is a paradigmatic anti-virulence
strategy that may prove efficacious against some of the most
pervasive and problematic bacterial pathogens. Chief among
these is Staphylococcus aureus, which remains one of the
most frequent causes of both hospital and community-acquired
infection (Lowy, 1998; Tong et al., 2015).
The propensity of S. aureus to acquire antibiotic resistance is
evidenced by the reoccurring clinical pattern whereby epidemics
caused by resistant isolates emerge rapidly after a new antibiotic
is introduced for infection control (Chambers and Deleo, 2009).
While S. aureus is classified as an opportunistic pathogen, theCell Reports 27, 187–198, April 2, 2019 ª 2019 The Authors. 187
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The agr System and Isolation of Apicidin
(A) Schematic of the agr system.
(B) Flowchart for isolation of apicidins from solid-state culture extracts.
(C) Chaetosphaeriaceae sp. (MSX53644) grown on PDA (scale bar, 10 mm).
(D) Fusarium sp. (G134 and G137) grown on PDA (scale bar, 10 mm).
(E) Apicidin structures.
(F) Preparative chromatogram (l = 254 nm) of the fraction used to purify compounds 1 and 2 from MSX53644.
(G) Preparative chromatogram (l = 254 nm) of the fraction used to purify compounds 2–4 from G134 and G137 (each chromatogram is representative of multiple
runs).capacity of highly aggressive USA300 lineages of methicillin-
resistant S. aureus (MRSA) to inflict disease among ‘‘healthy’’
community-dwelling individuals has reached pandemic propor-
tions (Chambers and Deleo, 2009; DeLeo et al., 2010; Otto,
2010). The hyper-virulent nature of ‘‘community associated’’
MRSA (CA-MRSA) strains has been attributed to heightened
expression of core genome-encoded virulence factors such as
a-hemolysin and a phenol soluble modulin (PSMa) peptides,
which subvert host defense by exerting cytolytic effects upon
immune effector cells (Cheung et al., 2011; Otto, 2010).
Like other S. aureus strains, MRSA utilizes quorum sensing to
synchronize virulence factor induction in proportion to prevailing188 Cell Reports 27, 187–198, April 2, 2019cell density (Novick and Geisinger, 2008; Thoendel et al., 2011).
Encoded by the agrBDCA operon, the quorum-sensing signaling
apparatus achieves maximal activity at high cell densities when
ambient agrBD-derived autoinducing peptides (AIPs) reach a
concentration threshold necessary to activate the AgrC-A two
component signal transduction system (Figure 1A). There are
four different types of AIP signal structures (AIP-I, -II, -III,
and -IV), and in turn four types of AgrC receptors, depending
on the S. aureus strain. The respective ligand receptor interac-
tion between AIP and the sensor histidine kinase AgrC initiates
the signaling cascade via phospho-transfer-mediated activation
of the response regulator AgrA. The DNA binding capability of
AgrA mediates distinct transcriptional pathways from the sys-
tems’ two oppositely oriented promoter units (Queck et al.,
2008). Whereas the P2 promoter activates an auto-induction cir-
cuit via agrBDCA expression, the P3 promoter exponentially in-
creases the system’s major effector molecule, RNAIII, which
regulates >200 virulence factor genes for the purpose of coun-
tering host defense and promoting tissue invasion (Kavanaugh
and Horswill, 2016; Novick and Geisinger, 2008; Thoendel
et al., 2011). Within the context of acute infection, agr-regulated
quorum sensing coordinates an explosive outburst of virulence
factors that are manifestly harmful to the host (Mayville et al.,
1999; Wright et al., 2005). As such, the therapeutic potential of
quorum-sensing inhibitors (often termed quorum quenchers)
has been intensively investigated (Daly et al., 2015; Figueroa
et al., 2014; Gordon et al., 2013; Muhs et al., 2017; Nielsen
et al., 2014; Quave et al., 2015; Sully et al., 2014; Wright et al.,
2005).
The overall goal of the present study was to identify quorum-
sensing inhibitors that prove efficacious as anti-MRSA interven-
tions. To this end, we discovered the potent activity of the
compound apicidin by screening a library of terrestrial, fresh-
water, and endophytic fungal metabolites, where apicidin was
biosynthesized by fungal strains of terrestrial (MSX53644; Chae-
tosphaeriaceae sp., Chaetosphaeriales, Ascomycota) and
endophytic (G134 and G137; Fusarium sp., Nectriaceae, Hypo-
creales, Ascomycota) origins. In a non-bactericidal manner,
apicidin-inhibited quorum-sensing activity across S. aureus iso-
lates, achieving low micromolar IC50s. Importantly, the translat-
ability of apicidin-mediated in vitro activity to efficacy in vivo
was confirmed in a cutaneous challenge model that also re-
vealed quorum-sensing interference within the infectious envi-
ronment. Consistent with the latter finding, apicidin treatment
enhanced polymorphonuclear neutrophil (PMN) accumulation
and function at cutaneous sites of infection. Together, these re-
sults indicate that apicidin-mediated inhibition represents a
promising strategy to limit MRSA virulence and promote host
defense.
RESULTS
Identification of Apicidin and Related Analogs as
S. aureus agr Inhibitors
The exploration of bioactive natural products has emerged as a
promising means of pursuing antimicrobial and anti-virulence
leads such as S. aureus quorum-sensing inhibitors (Cech and
Horswill, 2013; Muhs et al., 2017; Quave and Horswill, 2014;
Quave et al., 2015; Todd et al., 2017). This approach recently
led to the identification and characterization of u-hydroxyemo-
din, an AgrA-antagonizing small molecule derived from the fun-
gus Penicillium restrictum (Daly et al., 2015; Figueroa et al.,
2014). In the present study, a class of fungal metabolites,
termed apicidins, were uncovered through separate screens of
both terrestrial and endophytic fungi. The terrestrial strain,
MSX53644 (Chaetosphaeriaceae sp., Chaetosphaeriales, Asco-
mycota), was cultivated over rice and subjected to purification
(Figure 1B) to yield two cyclic tetrapeptides that were identified
using HRESIMS andNMR as the known natural product, apicidin
(2), and a new natural product analog of apicidin, which wasnamed apicidin L (1) (Figure 1E). In a parallel analysis, endophytic
fungi from medicinal plants were studied. LC-MS analysis of en-
dophytes (G135 andG137), whichwere isolated from the roots of
yerba mansa (Anemopsis californica [Nutt.] Hook. and Arn.
[Saururaceae]) (Bussey et al., 2015), showed the presence of api-
cidin by matching retention time, HRESIMS, and tandem mass
spectrometry data (El-Elimat et al., 2013) (Figures S1–S3).
Considering our interest in this class of compounds, and in an
attempt to isolate more structurally related analogs, these sam-
ples were further purified using reversed-phase preparative
high-performance liquid chromatography (HPLC) to yield more
apicidin (2) and two structurally related analogs: apicidin A (3)
and apicidin D2 (4) (Figures 1E–1G).
The bioactivity of apicidin and its analogs were screened via
in vitro assays that examined the ability of the compounds to
suppress S. aureus agr activation in a nonbiocidal manner
(Quave and Horswill, 2014). Beginning with well-established
agr P3 reporter based assays, time course experiments
measuring the dose effects of apicidin and analogs showed
potent activity against all agr types with negligible effects upon
bacterial growth (Figure 2A; Table S1). Similarly, apicidins’ broad
suppression of agr activation was corroborated in parallel exper-
iments measuring inhibition of red blood cell (RBC) lysis. In all
cases, apicidin and analogs mediated agr inhibition at IC50
values in lowmicromolar concentrations that were sub-inhibitory
for growth. Interestingly, agr types II and IV represented themost
sensitive and resistant alleles to apicidins’ impact, respectively.
Relative to its analogs, apicidin (2) showed the most impressive
actions as an agr inhibitor (Figure 2), and, therefore, became the
focus of our subsequent efforts to evaluate its efficacy as a
nontoxic, pan inhibitor of agr activation. Further corroboration
of the broad inhibitory effects of this compound on a per cell
basis was demonstrated via flow cytometry using the same agr
P3 reporter strains (Figure S4).
To evaluate the impact of apicidin on global transcriptional
regulation, we conducted RNA-seq analysis upon USA300
MRSA wild-type (WT) cultures grown in the presence of apicidin
or vehicle control. For purposes of comparing the effects of api-
cidin on the MRSA transcriptome to those of an agr null, we
performed parallel RNA-seq analysis of the WT and Dagr
preparations. Using a 4-fold cutoff as the threshold for differen-
tial gene expression, we found that apicidin altered the expres-
sion of thirty genes, with many of these representing prototypical
agr targets, such as hla, RNAIII, psma, and spl genes (Figure 2B;
Table S2). Together, these data corroborate and extend upon the
inhibitory capability of apicidin by demonstrating a transcrip-
tional signature that is largely confined to agr-regulated tran-
scripts, and most impressively suppressive against cytolytic
toxin induction (Figure 2B). Congruent with the apicidin-induced
inhibition of agr-regulated virulence factors, we observed
enhanced whole blood killing of MRSA when bacteria were
cultured in the presence of apicidin prior to inoculation
(Figure 2C).
Next, we conducted a series of in vitro assays to systemati-
cally assess the relative contribution of each of the core
genetic elements of the agrBDCA operon (Figure 1A). The mem-
brane-embedded peptidase AgrB is responsible for the first
step, by processing the AgrD pro-peptide into the functional,Cell Reports 27, 187–198, April 2, 2019 189
Figure 2. Apicidin Inhibits MRSA agr Function by Targeting AgrA
(A) Apicidin (apicidin L, apidicin, apicidin A, apicidin D2) mediated suppression of agr-P3 reporters (inhibition extends to all four agr types). Post-test *p < 0.05,
**p < 0.01, and ***p < 0.005; n = 10.
(B) USA300MRSA LAC genes showing >4-fold change in expression after treatment with 100-mMapicidin versus DMSO vehicle control (n = 3), determined using
RNA sequencing (RNA-seq). For comparison, gene expression was alsomeasured in the agrmutant treated with DMSO. Numbers for genes of unknown function
correspond to locus tags SAUSA300_XXXX.
(C) Heparinized human whole blood was inoculated with MRSA organisms cultured (4 h) in the presence of 100-mmapicidin or vehicle (n = 8). After 1 h, CFUs from
inoculated whole blood were plated out and compared with the starting inoculum and reported as percent killing. Error bars represent SEM. Post-test *p < 0.05.
(D) Mass spectrometric measurements comparing ambuic acid and apicidin’s impact on AIP levels in MRSA WT (blue bars, labeled WT) and constitutive AIP-
producing (red bars, labeled agrBD) strains. Each compound was tested at 100-mM concentration (n = 3). Statistical analysis was performed using the Student’s
t test, ****p < 0.001.
(E) Effect of increasing concentrations of apicidin L on reporter strains for WT AgrC versus constitutive AgrC*. Apicidin L is compared to the AIP-II inhibitor control
(representative; also performed with same results on apicidin, n = 3).
(F) Effect of increasing concentrations of apicidin, apicidin A, and apicidin D2 on P3-lux reporter activation using an agr null strain containing an agrA plasmid
(n = 4). Post-test *p < 0.05, **p < 0.01, and ***p < 0.005.extracellular AIP signal. To determine if apicidin inhibits agr
function at the level of AIP signal generation, we used an
established system whereby AIP is constitutively produced in
an engineered USA300 MRSA strain (Todd et al., 2017). This
engineered strain (labeled agrBD) decouples AIP signal biosyn-
thesis from quorum-sensing regulation, enabling quantitative
mass spectrometric analysis of culture supernatants to deter-
mine AIP levels (Figure 2D). An inhibitor that targets AgrB or
another aspect of AIP signal biosynthesis is expected to pre-
vent AIP production in both WT and engineered S. aureus
strains, while an inhibitor targeting another competent of
the agr system would only prevent AIP production in the
WT strain. Consistent with these predictions, ambuic acid, a
known agr signal biosynthesis inhibitor (Todd et al., 2017),
significantly inhibited AIP peptide production by both strains.
In contrast for apicidin, the WT strain was significantly inhibited
by 35%, while no statistically significant inhibition was
observed for the constitutive AIP-producing strain (Figure 2D).190 Cell Reports 27, 187–198, April 2, 2019The results of these experiments suggest that apicidin does
not target AgrB function or the signal biosynthesis process in
general.
Next, we explored the possibility that apicidin interferes with
the sensory activity of AIP receptor AgrC. Toward this goal, we
employed an R238H construct bearing a point mutation that
confers constitutive AgrC activity (Daly et al., 2015; Geisinger
et al., 2009), and thereby enables phosphoactivation of AgrA to
occur independently of AIP binding. With a hemolysis readout,
apicidin L (1) imposed a dose-dependent inhibition of lytic activ-
ity on AgrC R238H that mirrored the response of AgrC WT (Fig-
ure 2E). In contrast, treatment with noncognate AIP-II, which
competitively binds and inhibits AgrC function (Gordon et al.,
2013), had no impact on AgrC R238H activation as expected.
These results suggest that apicidin mediates its effects down-
stream of AgrC activation.
Finally, we set out to determine if AgrA serves as the target
of apicidin. To this end, we employed an agr P3 lux reporter,
Figure 3. Apicidin Abates MRSA Pathogenesis
(A and B) Representative images of tissue injury following infection with MRSAWT or Dagrmutant (±5 mg apicidin) and corresponding skin lesion size and weight
loss and measurements following infection for the indicated groups in BALB/c (n = 20) (A) and C57BL/6 mice (n = 5) (B). Error bars represent SEM. Post-test
*p < 0.05 and **p < 0.01.
(C) Representative images showing decreased bacterial burden in apicidin-treated animals relative to Dagr or vehicle controls 1 day after intradermal challenge
with 2 3 107 CFUs MRSA Lux+ or its agr null counterpart.
(D) Corresponding noninvasive, longitudinal measurements of bioluminescence following skin infection with MRSA Lux+ or Dagr Lux+ (n = 8).
(E) CFUs recovered from BALB/c skin lesions 1 day after infection (n = 5).where bioluminescence can only be achieved with expression of
AgrA (Sully et al., 2014). The dose-dependent inhibition of
agr-P3-driven bioluminescence shows that apicidin specifically
interferes with AgrA-dependent quorum-sensing activation (Fig-
ure 2F). Considering the strain used is agr type I, apicidin (2)
worked the best, while apicidin A (3) and D2 (4) were less effec-
tive, but still significantly inhibited. Taken together, these mech-
anistic studies provide compelling evidence that AgrA serves as
the molecular target of apicidin.
Apicidin Abates MRSA Pathogenesis
S. aureus causes 76% of skin infections (Moran et al., 2006),
more than any other infectious agent. Having demonstrated
apicidin’s potent quorum-sensing inhibition in vitro, we
next investigated the translatability of this activity within a
relevant infectious context in vivo during skin infection using
approaches developed by our group (Muhs et al., 2017;
Paharik et al., 2017; Todd et al., 2017). For this purpose, an
intradermal challenge model was employed by delivering a
single 5-mg dose of apicidin as part of the MRSA inoculum
suspension. To assess the contribution of differential immune
skewing of the host to any apicidin-induced effects, we
employed both C57BL/6 and BALB/c mice in our initial chal-lenge experiments. Irrespective of murine strain background,
apicidin treatment significantly reduced skin ulceration size
and weight loss following MRSA challenge (Figures 3A and
3B). Together, these data show that when applied as an
anti-infective, apicidin impressively attenuates MRSA-induced
disease following MRSA challenge.
To determine the impact of apicidin on cutaneous bacterial
burden, challenge experiments were conducted with a MRSA
Lux+ strain and compared against analogous challenges
with its agr deletion construct Dagr Lux+. An advantage of this
approach is the noninvasive and longitudinal manner with which
bacterial burden can be measured. While an apicidin-induced
decrease in bacterial burden was observed throughout the
experiment, this effect was most impressively evident one day
following infection, where it closely approached values obtained
afterDagr Lux+ challenge (Figures 3C and 3D). Corroborating the
apicidin-mediated enhancement of bacterial clearance via IVIS
imaging, significantly fewer CFUs were recovered from lesional
skin one day after infection in apicidin treated mice relative to
controls (Figure 3E). In addition, parallel analysis of lesion
development in the same apicidin and control mice showed a
correspondence between MRSA-driven bioluminescence and
dermatopathology.Cell Reports 27, 187–198, April 2, 2019 191
Figure 4. Apicidin-Mediated Quorum-
Sensing Inhibition Corresponds with Atten-
uated Skin Injury
(A) Images of agr-P3 reporter activity (biolumi-
nescence) 3 h post infection (±5 mg apicidin).
(B) Kinetics of agr activation in apicidin and
vehicle-control-treated mice after infection (n = 5).
(C) Representative images of apicidin or control
groups at the indicated time points after infection
(n = 5).
(D) Skin lesion size measurements at the indicated
time points after infection. Error bars represent
SEM. Post-test *p < 0.05 and **p < 0.01.Apicidin Mediates Quorum Quenching at In Vivo Sites of
Infection
Having demonstrated that apicidin attenuated MRSA-induced
illness (e.g., tissue damage, weight loss, bacterial burden), we
set out to determine if these therapeutic effects corresponded
with quorum-sensing interference in vivo. Based on previous
work by Wright et al., which showed that the extent of
S. aureus-induced dermatopathology is proportional to the
magnitude of agr activation during the first 4 h of infection (Wright
et al., 2005), we selected this key time period for in-depth anal-
ysis of the apicidin impact against multiple agr types in vivo. By
challenging mice with an agr-P3 lux reporter strain and moni-
toring the early kinetics of agr activation, we showed that the
attenuation of MRSA virulence in apicidin-treated animals
occurred alongside a significant interference of agr activation
in vivo (Figures 4A and 4B). To further demonstrate that the level
of agr interference mediated by apicidin corresponded with a
hypo-virulent infectious phenotype, we measured the ensuing
skin ulcers in these animals over a 14-day period and found a
dramatic reduction in cutaneous injury in apicidin-treated ani-
mals (Figures 4C and 4D). Altogether, these data demonstrate
that the apicidin-mediated attenuation of MRSA pathogenesis
corresponds with quorum-sensing inhibition both in vitro and
in vivo.
In Vivo Efficacy of Apicidin Extends to agr Type-II
Isolates
We next set out to investigate the potential of apicidin to show
broad spectrum in vivo efficacy against multiple S. aureus agr
types. To this end, the capacity of apicidin to influence the infec-
tious outcome following intradermal challenge with a USA100
MRSA, agr type II, invasive isolate was assessed. As observed
in analogous challenge experiments with agr type I strains, api-
cidin-treated animals exhibited significant attenuation in
USA100-induced dermonecrotic injury relative to controls (Fig-
ures 5A and 5B). By engineering an agr P3-lux reporter into192 Cell Reports 27, 187–198, April 2, 2019this agr type II isolate, we showed that
the protective effects of apicidin treat-
ment against multiple agr types corre-
sponds with real-time quorum quenching
at the cutaneous challenge site (Figures
5C and 5D). Carrying out the P3-lux-in-
fected animals further corresponded
with a significant reduction in lesion sizeat day 4 (Figure 5E), demonstrating the importance of early inter-
vention in agr signaling with the different USA100 lineage.
Apicidin Treatment Enhances PMN Responses after
MRSA Skin Challenge
Given that apicidin exposure is nontoxic to MRSA in vitro, the
impressive decrease in MRSA burden observed during in vivo
infection could be a function of enhanced staphylocidal host im-
mune responses. The recruitment of PMNs to sites of cutaneous
S. aureus infection is critical for pathogen clearance (Miller and
Cho, 2011; Spaan et al., 2013). Abundant in the circulation,
PMNs orchestrate protective anti-S. aureus cutaneous immune
responses by extravasating through vascular endothelium prox-
imal to infectious foci where they sequentially accumulate,
phagocytose, and clear S. aureus organisms (Spaan et al.,
2013). By performing challenge experiments with MRSA GFP+,
we were able to show that the apicidin-induced attenuation of
MRSA injury and burden corresponded with an increase in the
number of phagocytic PMNs accumulating at cutaneous chal-
lenge sites (Figure 6A). The frequency of MRSA uptake was un-
altered between apicidin and vehicle-exposed PMNs, which
matched control experiments that showed no significant impact
of apicidin on PMN function (Figure S5). Nonetheless, there was
an aggregate increase in the phagocytic capacity of the entire
PMN infiltrate during infection with the apicidin-treated group
(Figure 6A). Furthermore, the apicidin-induced increase in PMN
infiltration was even further surpassed in the setting of agr null
challenge, revealing an inverse proportionality between the
magnitude of agr activity and the strength of the ensuing PMN
response. Meanwhile, the lack of an effect on cutaneous PMN
infiltration following mock challenge indicates that apicidin’s
impact on PMN responses during infection are largely a conse-
quence of agr interference (Figure 6B).
To explore the possibility that apicidin exposure increases the
resistance of host cells to agr-regulated virulence factors, we
examined the prophylactic effects of apicidin administration
Figure 5. Apicidin-Mediated Attenuation of
MRSA Pathogenesis and In Vivo Quorum
Quenching Observed against Multiple agr
Types
(A) Skin lesion measurements following infection
with 2 3 107 CFUs of an agr type-II invasive
USA100 MRSA isolate (±5 mg apicidin). Error bars
represent SEM. Post-test *p < 0.05 and **p < 0.01
(n = 5).
(B) Representative images of tissue injury following
infection with agr type-II ± apicidin.
(C) Kinetics and representative images (1-h time
point; right) of agr-P3-induced bioluminescence
after intradermal challenge with 1 3 107 CFUs of
an agr type-II P3-lux reporter (± apicidin; n = 5).
Error bars represent SEM. Post-test *p < 0.05 and
**p < 0.01.
(D) Corresponding skin lesion size measurements
at the indicated time points following infection with
strain described in (C) (n = 8). Error bars represent
SEM. Post-test *p < 0.05 and **p < 0.01.
(E) Representative images of tissue injury (day 4)
following infection with agr type-II reporter
described in (C).against sterile challenge with cytotoxin-containing MRSA super-
natants. The similar degree of dermonecrotic injury sustained by
apicidin and control groups following MRSA intoxication sug-
gests that apicidin’s ability to attenuate infectious injury is princi-
pally achieved by limiting host cell exposure to agr-induced
virulence factors (Figure 6C). In view of the correlation between
MRSA-induced disease attenuation and cutaneous PMN accu-
mulation, we investigated the dependence of apicidin’s thera-
peutic effects upon the latter. To this end, we depleted host
PMNs via administration of an anti-Ly6G antibody on both the
day prior to and the day of infection. The equivalent severity of
skin ulceration and bacterial burden within the context of neutro-
penia demonstrates that apicidin’s therapeutic efficacy requires
a functional PMN compartment (Figure 6D). Taken together,
these findings indicate that the capacity of apicidin to bolster
host defense and improve disease outcome was largely a by-
product of agr inhibition, which in turn sensitizes MRSA for
PMN-mediated phagocytic clearance.
To better understand the mechanistic basis of the apicidin-
induced increase in PMN density at cutaneous sites of infection,
we assessed the cytokine milieu of lesional tissue one day after
infection. Interestingly, the apicidin-induced increase in cuta-
neous PMNs did not correspond with a commensurate increaseC
in prototypical PMN chemoattractant or
granulopoiesis factors. In fact, prepara-
tions from apicidin-treated animals
showed a decrease in the production of
CXCL-1 and granulocyte-colony stimu-
lating factor (G-CSF) relative to controls,
suggesting that apicidin’s ability to boost
PMN responses does not occur as a
result of alleviating a MRSA-induced
strain upon factors that mediate extrava-
sation into infected tissue (Figure 7A). Infurther support of this, equivalent cutaneous endothelial cell re-
covery and PMN abundance in the peripheral blood (PB) was
observed between apicidin-treated and control mice (Figure 7B).
While similar PMN counts in the skin-draining lymph nodes (LNs)
suggests that altered trafficking to alternative sites known to har-
bor PMNs after skin infection plays little role in the apicidin-
induced increase in cutaneous PMN accumulation (Figure 7C).
Together, these data suggest apicidin’s capacity to enhance
PMN infiltration is chiefly the result of alterations within the infec-
tious microenvironment.
Given that extraordinary expression of agr-regulated cytolytic
toxins is a defining feature of USA300 MRSA-induced disease,
we explored apicidin’s impact upon PMN persistence within
the infectious environment. Because PMN apoptosis-efferocy-
tosis is the cellular fate that is most advantageous to the host,
it was important to distinguish the rate of cell death between
PMNs that are actively executing the effector function of
MRSA uptake (GFP+) and those that have not. To this end, we as-
sessed the frequency of PMNs in late stage apoptosis-necrosis
within lesional skin preparations of MRSA GFP+ challenged
mice. For the phagocytic and non-phagocytic PMNs, we
observed an apicidin-induced decrease in the frequency of
PI+, late-stage apoptotic-necrotic cells (Figure 7D), althoughell Reports 27, 187–198, April 2, 2019 193
Figure 6. Apicidin Treatment Enhances PMN Responses after MRSA Skin Challenge
(A) Gating strategies (top) for identification of PMNs recovered from lesional skin and corresponding PMN accumulation values (bottom) 1 day after intradermal
challenge with 2 3 107 MRSA WT expressing GFP (± apicidin) or its agr null counterpart (n = 8). Error bars represent SEM. Post-test *p < 0.05 and **p < 0.01.
(B) Gating strategy (left) and enumerated PMNs (right) 1 day after intradermal saline challenge (± apicidin; n = 8).
(C) Representative skin injuries 4 days after sterile challenge (intradermal) with 30 mL ofWTMRSA supernatant at the skin sites intradermally inoculated with saline
(± apicidin) 3 h prior (n = 6).
(D) Representative bioluminescence images 1 day after intradermal challenge (2 3 107 CFUs MRSA Lux+) among apicidin-treated and control groups receiving
100 mg of the PMN-depleting anti-Ly6G antibody or isotype control via intraperitoneal injection administered both the day prior and the day of infection. Cor-
responding time course values (right) of MRSA burden for the indicated groups (n = 6).
(E) Representative images of skin injury (left) and corresponding lesion size measurements 4 days after infection for the indicated groups (n = 5). Error bars
represent SEM. Post-test *p < 0.05 and **p < 0.01.not quite to the same level as the agr mutant. Together, these
data suggest that apicidin impacts the host-pathogen interface
by suppressing agr-regulated virulence factors, especially im-
mune cell lysing toxins, and thereby extends cytoprotective ef-
fects upon cutaneous PMNs.
DISCUSSION
Since the advent of antibiotic therapy, S. aureus has evolved
resistance to every frontline antibiotic used in healthcare settings
and done so with devastating human health effects. Considering
that ancestral S. aureus is highly sensitive to virtually every anti-
biotic ever devised, the broad resistance features of today’s
most pervasive and problematic isolates suggest that modern
medicine’s reliance on antibiotic therapy has spurred resistance
development (Chambers and Deleo, 2009; DeLeo and Cham-
bers, 2009; Spellberg et al., 2015). Pandemic CA-MRSA pro-
vides an illustrative example of how infectious transmissibility
brought on the concurrent evolution of antibiotic resistance
and hyper-virulence (Cheung et al., 2011; Otto, 2010). Consid-
ering that MRSA is already one of the most pervasive and prob-194 Cell Reports 27, 187–198, April 2, 2019lematic causes of bacterial infection, the continuation of such
trends poses a serious threat to public health and highlights
the need for new treatments. Through quorum-sensing inhibition
and immune boosting, apicidin treatment offers a therapeutic
strategy to sensitize MRSA to host-mediated clearance in a
resistance-avoiding fashion.
Herein, we report efficacious application of apicidin as an anti-
virulence agent. Apicidin’s activity as a pan-quorum-sensing in-
hibitor was confirmed via assays that demonstrated suppression
of agr activation of all types in a non-biocidal manner. Further ev-
idence of agr interference was achieved via RNA-seq analysis,
showing that the majority of apicidin-affected transcripts were
agr-regulated and included the prototypical cytolytic toxins hla
and psms. To determine the apicidin target within the agr ma-
chinery, assays specific to each component were employed,
surprisingly narrowing the activity to AgrA (Figure 2). Based on
the cyclic peptide-like nature of the apicidin structure (Figure 1),
we anticipated that the AgrC receptor would be the target, in
similar fashion to synthetic AIP derivatives (Gordon et al., 2013,
2016). However, the ability of apicidin to definitely inhibit the
constitutive AgrC R235H construct, and also prevent AgrA
Figure 7. Apicidin Confers Cytoprotective Effects upon Skin-Infiltrating PMNs after MRSA Skin Challenge
(A) Supernatants from skin tissue homogenates were collected 1 day after infection and subjected to cytokine array analysis (n = 6).
(B) Gating strategies (left) and enumeration of (right) CD31+ CD45 endothelial cells recovered from lesional tissue 1 day following MRSA challenge (± apicidin) or
its agr null counterpart (n = 6).
(C) Gating strategies (left) and enumeration of PMNs (right) in PB and skin-draining LNs 1 day after MRSA skin challenge (n = 6).
(D) Gating strategies (left) and corresponding frequency values (right) for propidium iodide+ phagocytic (GFP+) and non-phagocytic (GFP) PMNs recovered from
skin lesions 1 day after intradermal challenge with 23 107 MRSA GFP+ (± apicidin) or its agr null counterpart (n = 5). Error bars represent SEM. Post-test *p < 0.05
and ***p < 0.001.activation of a P3-lux reporter, strongly indicated that AgrA is the
actual target. Thus, apicidin joins savarin and u-hydroxyemodin
(which is another fungal metabolite) as the known AgrA inhibitors
(Daly et al., 2015; Sully et al., 2014). Additional work will be
required to identify the precise AgrA residue(s) that is required
for its interaction with apicidin and to further define the mecha-
nism of apicidin inhibition.
The translatability of apicidin’s agr inhibitory activity to in vivo
therapeutic efficacy was confirmed using a MRSA intradermal
challenge model. As a single-dose intervention, apicidin amelio-
rated multiple measures of clinical disease severity. While a
number of agr inhibitors have shown the ability to attenuate cuta-neous ulcer formation following MRSA challenge (Daly et al.,
2015; Mayville et al., 1999; Muhs et al., 2017; Quave et al.,
2015; Sully et al., 2014), apicidin is first to show that its efficacy
extends to multiple agr types using infection models, demon-
strating its broad utility as an anti-infective agent. Although, agr
type-I alleles, which encompass USA300 isolates, are the most
pervasive and problematic clinically (Chambers and Deleo,
2009; DeLeo et al., 2010), other agr types represent a source
of human disease (Tong et al., 2015). For instance, isolates
bearing agr type-II alleles are the leading cause of hospital-ac-
quired MRSA infection (Limbago et al., 2009). Thus, the applica-
bility of any quorum-targeting therapy is extended by its capacityCell Reports 27, 187–198, April 2, 2019 195
to inhibit multiple agr types. Consistent with the attenuation of
dermonecrotic injury, the single-dose efficacy of apicidin corre-
sponded with significant agr interference within the in vivo infec-
tious environment following cutaneous challenge with both
type-I and type-II MRSA isolates. As previously demonstrated
by Novick’s group (Wright et al., 2005), the explosive activation
of the agr system occurring within the first few hours of in vivo
infection largely dictates the severity of MRSA-induced disease.
Consistent with this, we recently showed that the potent agr
antagonism of S. caprae-derived AIP had only a minor benefit
as treatment for established MRSA skin infection (Paharik
et al., 2017). With this in mind, pharmacologically abating
MRSA pathogenesis via quorum-sensing inhibition will require
targeting agr activity during a narrow temporal window that
can ensue rapidly after tissue penetration. Thus, it appears that
as a potential clinical intervention, the application of apicidin is
best suited as a prophylactic agent.
MRSA is a major contributor to the ever-escalating threat of
antibiotic resistant bacterial pathogens. Among the core stra-
tegic approaches of the National Institutes of Allergy and
Infectious Diseases’ antibacterial resistance program are the
development of (1) anti-virulence strategies that disarm without
directly killing bacteria and (2) immunological interventions that
enhance host defenses. The present study demonstrates that
these paradigms are complementary in the coordination of
host defense, namely, the enhanced effector functionality within
the cutaneous PMN network. Both clinical and experimental
findings concordantly suggest that the staphylocidal functions
of skin-infiltrating PMNs are essential for protective anti-
S. aureus immunity (Miller and Cho, 2011; Spaan et al., 2013),
in contrast to steady-state skin, which is largely devoid of
PMNs. Infectious injury activates cytokine-chemokine circuits
that in turn forge an inflammatory milieu replete with PMN
recruitment, survival, and differentiation factors. Within the
context of S. aureus skin infection, local production of the quin-
tessential inflammatory mediator IL-1b incites cytokine-chemo-
kine pathways that underlie PMN recruitment and function (Miller
andCho, 2011; Spaan et al., 2013).While IL-1b is clearly required
for S. aureus host defense, the results from the present study
show that increased IL-1b output (as observed in control groups)
does not necessarily yield commensurate gains in cutaneous
PMNs (Figures 6 and 7). In fact, PMN numbers were greatest
in agr-null-challenged tissue where IL-1b production was the
lowest. These findings suggest that protective anti-MRSA
effector responses may be optimal in conditions where local
inflammation is finely tuned. Consistent with this notion, apicidin
treatment augmented cutaneous PMN responses and hastened
MRSA clearance, while subduing inflammatory cytokine produc-
tion. The inverse relationship between PMN accumulation and
the bacterial burden resulting from apicidin treatment is reminis-
cent of prior work demonstrating the therapeutic efficacy of
S. caprae AIP. Using a similar model of intradermal challenge,
Paharik and Parlet et al. showed that one of the most striking
alterations imposed upon the host-pathogen interface via phar-
macological targeting of MRSA quorum sensing is increased
PMN amassment at sites of infection (Paharik et al., 2017). The
present study further clarifies the mechanistic basis for this
occurrence by showing that quorum-sensing inhibition confers196 Cell Reports 27, 187–198, April 2, 2019cytoprotective effects to skin-infiltrating PMNs. When viewed
together, these results are consistent with the following interpre-
tation: By disabling S. aureus quorum sensing, the resultant sup-
pression of immune-toxigenic virulence factors (e.g., PSMs and
a-toxin) increases the survival of PMN effectors that mediate
pathogen clearance, the manifestations of which are attenuated
tissue damage and accelerated bacterial clearance.
In conclusion, we report the efficacious application of the
fungal derivative apicidin as an anti-virulence intervention
against MRSA-induced disease. As the threat posed by anti-
biotic-resistant pathogens continues to grow, there is an urgent
need for innovative approaches that are mechanistically distinct
from conventional antibiotic therapy, and are tailored for the
pathophysiology of specific infectious agents. Apicidin exem-
plifies such a pioneering treatment modality. By inhibiting
virulence factor expression, apicidin impacts host-pathogen
interactions in a manner that favors immune clearance of the
pathogen and blocks disease progression.
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anti-mouse Ly6C (HK1.4) Biolegend Cat# 128016
anti-mouse CD45 (30-F11) Biolegend Cat# 103134
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anti-mouse/human CD11b (M1/70) Biolegend Cat# 101226
rat anti-mouse CD16/32 FcgRIII/II (2.4G2) Dr. Thomas Waldschmidt,
Univ. of Iowa
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Bacterial and Virus Strains
Chaetosphaeriaceae sp. [Sordariomycetes, Ascomycota] Mycosynthetix MSX53644
Fusarium sp. This work G134
Fusarium sp. This work G137
S. aureus Restriction deficient cloning host Lab collection RN4220
S. aureus MN EV, agr type IV Lab collection AH407
S. aureus 502a + pDB59 cmR, YFP reporter, agr type II Lab collection AH430
S. aureus MW2, agr type III Lab collection AH843
S. aureus USA300 agr type I Boles et al., 2010 AH845
S. aureus USA300 CA-MRSA ErmS (LAC*) Boles et al., 2010 AH1263
LAC* Dagr::tet Kiedrowski et al., 2011 AH1292
AH845 + pDB59 cmR, YFP reporter, agr type I Kirchdoerfer et al., 2011 AH1677
MW2 + pDB59 cmR, YFP reporter, agr type III Kirchdoerfer et al., 2011 AH1747
MN EV + pDB59 cmR; YFP reporter, agr type IV Kirchdoerfer et al., 2011 AH1872
LAC* agrP3::luxABCDE Figueroa et al., 2014 AH2759
LAC* Dagr::tet + pCM29 cmR (GFP) Paharik et al., 2017 AH2768
LAC* Dagr::tet, 411::LL29 sarAP1-agrBD Todd et al., 2017 AH2989
RN4220 Dagr::ermB agrP3::luxABCDE + pEPSA5-agrA Sully et al., 2014 AH3048
JE2 agrC::FNS, 411::LL29 + pRMC2-agrBDCA Daly et al., 2015 AH3469
JE2 agrC::FNS, 411::LL29 + pRMC2-agrBDCA (agrC R238H) Daly et al., 2015 AH3470
LAC* + pCM29 cmR (GFP) Pang et al., 2010 AH3669
S. aureus USA100 MRSA blood isolate IA116 Daniel Diekema AH3684
LAC* Lux Todd et al., 2017 AH3700
LAC* Dagr::tet Lux Paharik et al., 2017 AH3774
USA100 IA116 agrP3::luxABCDE This work AH4390
Biological Samples
Rabbit defibrinated blood 250 mL HemoStat Laboratories Cat# DRB250
Chemicals, Peptides, and Recombinant Proteins
Trypsin VWR Life Sciences Cat# 90002-07-7
Collagenase Type II Gibo Cat# 9001-12-1
Propidium iodide Biolegend Cat# 421301
Annexin V Biolegend Cat# 640919
Chloramphenicol Sigma Cat# C0378
Ambuic acid Apidogen Life Sciences Cat# AG-CN2-0129-M001
S. aureus AIP-II Anaspec Peptide# 61088
Apicidin Sigma Cat# A8851
(Continued on next page)
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RNAprotect QIAGEN Cat# 76526
Lysostaphin Sigma Cat# L7386
Formic Acid (Optima Grade) Fisher Scientific Cat# A117-50
Acetonitrile (Optima Grade) Fisher Scientific Cat# A955-4
Acetonitrile (HPLC Grade) Fisher Scientific Cat# A998SK-4
Water (Optima Grade) Fisher Scientific Cat# W6-4
Stemsol (DMSO) Protide Pharmaceuticals Cat# PP1350
Critical Commercial Assays
Mouse magnetic Luminex Assay R&D Systems Custom
RNeasy Mini kit QIAGEN Cat# 74104
Turbo DNA-free kit Fisher Scientific Cat# AM1907
Ribo-Zero rRNA Removal Kit (Gram-Positive Bacteria) Illumina Cat# MRZGP126
TruSeq Stranded mRNA Library Prep Kit Illumina Cat# RS-122-2103
Deposited Data
RNaseq data This work GenBank: SRP182661
Chaetosphaeriaceae sp. ITS spacer and 28S rRNA This work GenBank: MF374619
Fusarium sp. G134 ITS spacer This work GenBank: KM816766
Fusarium sp. G137 ITS spacer This work GenBank: KM816768
Experimental Models: Organisms/Strains
C57BL/6N mice Charles River Laboratories Strain code 027
BALB/c mice Charles River Laboratories Strain code 028
Oligonucleotides
CTTGGTCATTTAGAGGAAGTAA IDT ITS1F
TCCTCCGCTTATTGATATGC IDT ITS4
Software and Algorithms
Living Image Software Xenogen Version 4.4
Flow Jo TreeStar Version 10.4
FACSDiva BD Version 8
CellQuest BD Version 5.1
ImageJ NIH N/A
Galaxie Chromatography Workstation Varian Version 1.9.3.2
SeqMan NGen DNASTAR Version 14
ArrayStar DNASTAR Version 14
PRISM GraphPad Version 7.0a
Other
TECAN plate reader TECAN LifeSciences Infinite M200
Stuart SI505 Microplate Shaking Incubator Cole-Parmer Item # EW-79520-08
Xenogen in vivo imaging system (IVIS) Caliper Life Sciences IVIS200
CombiFlash RF system Teledyne-Isco Unit ID: 625230006
Q Exactive Plus orbitrap mass spectrometer Thermo Fisher N/A
Acquity UPLC Waters Product No: Photodiode Array el
Detector – 186015033
Acquity UPLC Waters Column Manager – 800000247
Acquity UPLC Waters Sample Manager – 186015006
Acquity UPLC Waters Binary Solvent Manager – 186015001
Acquity BEH C18 UPLC column Waters 186002350
Prostar HPLC Varian N/A
Gemini-NX C18 (analytical) Phenomenex 00G-4435-E0
(Continued on next page)
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Gemini-NX C18 (preparative) Phenomenex 00G-4435-P0-AX
130 g Redisep RF C18 column Teledyne-Isco Cat# 69-2203-337
LTQ Orbitrap XL mass spectrometer Thermo Fisher N/A
ECA-500 NMR Spectrometer JEOL N/A
Luminex 200 Luminex N/A
FACS LSR II BD N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and request for resources should be forwarded to and will be fulfilled by the Lead Contact, Dr. Alexander R. Hor-
swill (alexander.horswill@ucdenver.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial strains and plasmids
For all experiments, S. aureus cultures were grown in a tryptic soy broth (TSB) at 37C with shaking at 200 rpm. Chloramphenicol
(Cam) was added to the media as needed at 10 mg/mL. Bacterial strains used are listed specifically in each method section and
in the Key Resource Table.
Mice
C57BL/6N or BALB/cmice (equal male and female numbers) were purchased from theCharles River and housed in specific pathogen
free facilities at the University of Iowa. Prior to their inclusion in the study, mice were allowed to acclimate to the ABSL-2 animal hous-
ing facility at theUniversity of Iowa for at least seven days. For in vivo studies, 8 to 20-week old age-matched, sex-matchedmicewere
randomly assigned to treatment groups and at experimental end points, mice were humanely euthanized using carbon dioxide inha-
lation. The animal studies were reviewed and protocol approved by the University of Iowa Institutional Animal Care and Use Com-
mittee. The University of Iowa is AAALAC accredited, and the centralized facilities meet and adhere to the standards in the ‘‘Guide
and Care of Laboratory Animals.’’
Plant material
Plant material of yerba mansa [Anemopsis californica (Nutt.) Hook. & Arn. (Saururaceae)] was collected with permission by Amy
Brown of Apache Creek Ranch in Santa Fe, NM (35350 56.4000N, 105500 27.2200W). A voucher specimen (NCU602027) was depos-
ited in the University of North Carolina Herbarium. The specimen was authenticated by Amy Brown.
Fungal strains
Fungal strain MSX53644 from Mycosynthetix library was stored, fermented, and extracted via well-established methods. Based on
GenBank BLAST search and molecular phylogenetic analysis using the internal transcribed spacers (ITS1-5.8S-ITS2) region and the
D1-D2 variable portion of the 28S rRNA large subunit gene of the nuclear RNA operon, as detailed previously (Raja et al., 2017),
MSX53644was identified asChaetosphaeriaceae sp. [Sordariomycetes, Ascomycota] (Figure S2D). The sequence data were depos-
ited in GenBank under accession numbers: MF374619, MF374620, MF374621, MF374622.
The endophytic fungal strains G134 and G137 were isolated from surface sterilized fresh roots of yerba mansa [Anemopsis cali-
fornica (Nutt.) Hook. & Arn. (Saururaceae)] using methods reported in detail previously (Bussey et al., 2015). Strains G134 and
G137 were found to be two isolates for the same strain and were identified as a Fusarium sp. by sequencing the internal transcribed
spacer region of the ribosomal RNA gene (ITS) using molecular methods (Raja et al., 2017). The ITS sequences for G134 and G137
were deposited in GenBank (accession number KM816766 for G134 and KM816768 for G137).
METHOD DETAILS
Quenching assays with reporter strains:
Apicidin was tested for quorum quenching activity against all four agr types using P3-YFP reporter strains AH1677 (type I), AH430
(type II), AH1747 (type III), and AH1872 (type IV) (Hall et al., 2013; Kirchdoerfer et al., 2011). Overnight cultures of reporter strains
that were grown in TSB supplemented with Camwere inoculated at a dilution of 1:250 into fresh TSB containing Cam. 100 mL aliquots
were added to 96-well microtiter plates containing 100 mL aliquots of TSB containing Cam and 2-fold serial dilutions of apicidin.
Readings were recorded at 30 min increments using a Tecan Systems Infinite M200 plate reader.Cell Reports 27, 187–198.e1–e6, April 2, 2019 e3
Hemolytic activity
A rabbit red blood cell (RBC) hemolysis assay based on previously describedmethods was used (Daly et al., 2015; Pang et al., 2010).
Overnight cultures of agr strain types I, II, III, and IV were inoculated 1:500 into 5 mL of TSB (in 17x150 mm culture tubes) containing
apicidin at concentrations of 100, 50, 25, 12.5, and 6.25 mg/mL. For assessing the impact on constitutive AgrC, strains AH3469 and
AH3470 were used in parallel with apicidin treatment as previously described (Daly et al., 2015). All cultures were incubated at 37C
with shaking (250 rpm), and growth was monitored by periodically transferring 100 mL of culture to a 96-well microtiter plate and
reading OD600 in a Tecan Systems Infinite M200 plate reader. Following incubation, 600 mL of each culture was filter sterilized using
cellulose acetate SpinX 0.22 mm filters. To quantify hemolytic activity, the filter sterilized culture supernatants from apicidin treated
cultures were diluted, and 50 mL aliquots were dispensed in quadruplicate into 96-well microtiter plates. Rabbit erythrocytes, were
added to the microtiter plates at 50 mL per well. The erythrocytes and culture supernatants were mixed and incubated statically at
room temperature for 2 hr. Hemolysis was detected by the loss of turbidity as measured at OD630 using a Tecan Infinite M200 plate
reader.
Mass Spectrometric Measurements of AIP
Experiments to evaluate the impact of apicidin on signal biosynthesis byMRSAwere conducted as described previously (Todd et al.,
2017). Briefly, 250 mL cultures of strains AH2989 (AIP constitutively producing strain (Todd et al., 2017)) and AH1263 (wild-type,
USA300 LAC (Boles et al., 2010)) were treated with 5 mL of 5 mM apicidin in DMSO, for a final concentration of 100 mM in the culture
media. The known signal biosynthesis inhibitor ambuic acid (also at 100 mM) served as a positive control, and vehicle (2% DMSO in
TSB) served as negative control. AIP I levels produced by both strains after 18 hr were measured directly from spent media using
ultraperformance liquid chromatography (Waters Acquity UPLC) coupled to high resolution mass spectrometry (Q-Exactive Orbitrap,
Thermo).
Fermentation, extraction and isolation
For chemistry studies, a 2.8-L Fernbach flask (Corning, Inc., Corning, NY, USA) containing 150 g rice and 300mLH2Owas inoculated
with as seed culture this strain that was grown in YESDmedium. After incubation for 14 days at r.t., the solid culture was extracted by
addition of a 500 mL mixture of 1:1 MeOH/CHCl3. Using a spatula, the culture was chopped into small pieces and left to shake at
125 rpm at r.t., followed by filtration. The solid residues were thenwashedwith 100mL of 1:1MeOH/CHCl3. To the combined filtrates,
900 mL CHCl3 and 1500 mL H2O were added so that the final ratio of CHCl3/MeOH/H2O was 4:1:5 and left to stir for 30 min. The
mixture was then transferred into as a separatory funnel and the organic bottom layer was drawn off and evaporated to dryness.
The dried organic phase was then re-constituted in 100 mL of 1:1 MeOH/CH3CN and 100 mL of hexanes and transferred into a sep-
aratory funnel. The MeOH/CH3CN layer was drawn off and evaporated to dryness under vacuum. The defatted crude material (1.2 g)
was dissolved in amixture of CHCl3/MeOH, adsorbed ontoCelite 545, and fractionated via normal phase flash chromatography using
a gradient solvent system of hexane/CHCl3/MeOH at a 40 mL/min flow rate and 53.3 column volumes over 63.9 min to afford five
fractions. Fraction 4 (300 mg) was subjected to preparative reversed-phase HPLC over a Phenomenex Gemini-NX C18 preparative
column using a gradient system of 40:60 to 70:30 over 30 min of CH3CN/H2O (acidified with 0.1% formic acid) at a flow rate of
21.24 mL/min (Figure 1F) to yield compounds 1 (4.1 mg) and 2 (3.0 mg) which eluted at 18.0 and 19.5 min, respectively. The
HRMS (Figure S1A) and 1H and 13C NMR data (Figure S1B) for compounds 1 and 2 were in agreement with the literature.
Fermentation, extraction and isolation of compounds from strains G134 and G137
Strains G134 and G137 were fermented and extracted using techniques akin to those described for strain MSX53644 above. The
extracts from G134 and G137 were combined, as the LC-MS analysis of the extracts showed similar chemical profiles, the two
cultures showed similar morphological characteristics, and decisively, the two isolates showed similar sequences of the internal tran-
scribed spacer region of the ribosomal RNA gene (ITS). The combined defatted extracts of G134 and G137 (125 mg) were then frac-
tionated using normal phase flash chromatography using a gradient solvent system of hexane/CHCl3/MeOH at a 18mL/min flow rate
and 68.1 column volumes over 18.2 min to afford five fractions. Fraction 5 (35 mg) was found to contain apicidin as evidenced by LC-
MS analysis and hence was subjected to preparative reversed-phase HPLC purification over a Phenomenex Gemini-NX C18 prepar-
ative column using a gradient system of 40:60 to 70:30 over 30 min of CH3CN/H2O (acidified with 0.1% formic acid) at a flow rate of
21.24 mL/min (Figure 1F) to yield compounds 2 (8.9 mg), 3 (1.7 mg), and 4 (1.5 mg), which eluted at 19.5, 15.5, and 17.5 min, respec-
tively. The HRMS (Figure S1A) and 1H and 13C NMRdata (Figure S1B) for compounds 2, 3 and 4were in agreement with the literature.
NMR methods
NMR data were collected using a JEOL ECA-500 NMR spectrometer operating at 500 MHz for 1H and 125 MHz for 13C (JEOL Ltd.,
Tokyo, Japan). Residual solvent signals were utilized for referencing. High resolution mass spectra (HRMS) were obtained using a
Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source (Thermo Fisher Scientific, San
Jose, CA, USA). Phenomenex Gemini-NX C18 analytical (5 mm; 250 3 4.6 mm) and preparative (5 mm; 250 3 21.2 mm) columns
(Phenomenex, Torrance, CA, USA) were used on a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar
335 photodiode array detector (PDA), with data collected and analyzed usingGalaxie ChromatographyWorkstation software (versione4 Cell Reports 27, 187–198.e1–e6, April 2, 2019
1.9.3.2, Varian Inc.). Flash chromatography was conducted on a Teledyne ISCO CombiFlash Rf using Silica Gold columns and moni-
tored by UV and evaporative light-scattering detectors (both from Teledyne Isco, Lincoln, NE, USA).
S. aureus skin infections
At D0, age, strain and sexmatched C57BL/6 or BALB/cmice were anesthetized with isoflurane, abdominal skin was carefully shaved
and exposed skin was cleansed by wiping with an alcohol prep pad. For inoculum preparation, a USA300MRSA LAC strain (AH1263)
(Boles et al., 2010), and strains engineered for constitutive bioluminescence via lux operon insertion (AH3700) or its agr null counter-
part (AH2989), or the LAC WT engineered to constitutively express green fluorescent protein (AH3669) or its agr null counterpart
(AH2768), were grown to mid-log-phase, pelleted and resuspended in DPBS to achieve 50 mL inoculum mixtures that contained
either 2 x107 CFUs ± 5 mg apicidin (diluted in neat DMSO). Apicidin or DMSO containing inoculums were injected intradermally
into abdominal skin. Baseline body weights of mice were measured before infection and every day thereafter for a period of
7-14 days. For determination of lesion size, digital photos of skin lesions were taken daily and analyzed via ImageJ software. For
the USA100 experiments, strain AH3684 (IA116, kindly provided by Dr. Daniel Diekema) was used. The plasmid for agr-P3 lux
was transformed into this strain for monitoring agr kinetics during infection (new strain AH4390).
Measurement of quorum quenching in vivo
Inoculum preparation for assessing quorum quenching in vivo. AnMRSA LAC reporter strain engineered to couple agr activation with
bioluminescence, called agr-P3 lux (AH2759) (Figueroa et al., 2014), was grown in TSB medium containing chloramphenicol over-
night at 37C in a shaking incubator set to 200 rpm. Overnight cultures were diluted 1:100 TSBwith chloramphenicol and subcultured
to an optical density of 0.1 at 600nm (z1 hr). Bacterial cells were then pelleted and resuspended in sterile saline. 50 mL inoculum
suspensions containing 1x107 CFUs and 5 mg of apicidin diluted in DMSO or DMSO alone were injected intradermally into abdominal
skin using 0.3 mL/31 gauge insulin syringe (as a technical control several mice were injected in the same manner with 50 mL of sterile
saline only. For all infections, challenge dose was confirmed by plating serial dilutions of inoculum on TSA and counting ensuing col-
onies after overnight culture. Beginning immediately after infection, mice were imaged under isoflurane inhalation anesthesia (2%).
Photons emitted from luminescent bacteria were collected during a 2 min exposure using the Xenogen IVIS Imaging System and
living image software (Xenogen, Alameda, CA). Bioluminescent image data are presented on a pseudocolor scale (blue representing
least intense and red representing the most intense signal) overlaid onto a gray-scale photographic image. Using the image analysis
tools in living image software, circular analysis windows (of uniform area) were overlaid onto abdominal regions of interest, and the
corresponding bioluminescence values (total flux) were measured and plotted versus time after infection.
Evaluation of skin and blood immune cells
For skin: abdominal skin ulcerationswere excised and incubated in trypsin (0.6% in PBS) for 75min at 37C; then cut into small pieces
and incubated in Collagenase type II (0.5 mg/mL RPMI) for 90min at 37C. Skin cell suspensions were generated by serial passage of
skin fragments through 18 and 20 gauge syringes. LN cell suspensionswere generatedmincing inguinal LNswith a razor blade before
serial passage of LN fragments through 18 and 20 gauge syringes. For whole blood: blood was collected, washed and re-suspended
in Tris-buffered ammonium chloride to lyse red blood cells. All tissue preps were passed through a 70 mm filter before staining.
Whole blood killing assays
For killing assays: PB was collected in sodium heparin tubes, transferred into round bottomed 96 well plates (Corning, NY). LAC cul-
tures were grown in the presence of apicidin (100 mM) or DMSO for 4 hr at 37C with shaking (250 rpm). After culture, cells were
washed in saline and resuspended to a concentration of z1x105 CFUs/mL. Cells exposed to Apicidin or control were then mixed
with heparinized PB in at a concentration of 1x106 CFUs/150 mL PB, the infected blood was incubated at 37C in a 37Cwith shaking
(250 rpm). After 1 h, serial dilutions in saline were performed to determine the endpoint numbers of CFU, which were compared to the
initial bacterial load to determine the viable percentage of the initial inoculum.
RNA Seq
RNaseq was essentially performed as previously described (Crosby et al., 2016). Briefly, cultures of LAC and LACDagrwere grown in
TSBwith DMSO alone or 100 mMapicidin (diluted in neat DMSO) in triplicate in a 48-well plate. Cultures were grown to optical density
of 4 at 600 nm, and cells were harvested and treated with RNAProtect Bacteria Reagent (QIAGEN). Cells were lysed using lysostaphin
and RNA purified using the RNeasy mini kit (QIAGEN). The samples were treated with DNA-free (Ambion) and sample quality was
affirmed via Bioanalyzer (Agilent). Ribosomal RNA was depleted using Ribo-Zero rRNA Removal Kit for gram positive bacteria
(Illumina). cDNA libraries were generated at the University of Iowa Genomics Division using the TruSeq Stranded mRNA Library
Prep kit (Illumina). Sample were barcoded, pooled and sequenced in 125x125 paired-end reads on an Illumina HiSeq 2000
sequencer. The resulting reads were aligned to an updated S. aureus USA300 genome file containing annotations for small RNAs
(Carroll et al., 2016) using SeqManNGen (DNASTAR) and reads were quantified using ArrayStar (DNASTAR). Genes were considered
differentially expressed if they showed aR 4-fold change in expression with 95% confidence as evaluated by Student’s t test with a
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Flow cytometry
For staining of skin, LN and whole blood preparations, the following antibodies: Anti-Ly6G (1A8), Anti-Ly6C (HK1.4), -CD11b (M1/70),
CD45 (30-F11) were purchased from BioLegend. To block nonspecific binding, cells were incubated with rat anti-mouse CD16/32
FcgRIII/II (2.4G2) and vortexed prior to surface staining. In all experiments, cells were collected on a LSR II using Diva software,
and analyzed using FlowJo software. Dead cells were excluded by low forward-scatter and side-light scatter. Spectral overlaps be-
tween fluorochrome channels were corrected by automated compensation on singly stained, positive controls for each fluoro-
chrome. In general, 50,000 cells were collected/tube. Flow cytometric analyses of bacterial cultures were conducted by incubating
MRSA subcultures in 100 mM apicidin, for the 4 or 7 hr in a Stuart incubator set to 37C, shaking at 1000 RPM. After, washing and
resuspending cultures in DPBS, samples were collected on a FACS LSR II using Diva software.
Cytokine Measurements from Tissue Homogenates
Biopsy punches (4mm), obtained from the center of skin ulcerations 1 day after infection, were homogenized with in sterile RPMI with
proteinase inhibitor cocktail. The supernatants from these preparations were incubated with amultiplex bead array for IL-1b, G-CSF,
KC (CXCL1), and CXCL2. Data were collected on a Luminex 200 (Luminex, Austin, TX, USA) and analyzed with Bio-plex manager
software 6.0.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
For each experiment, the total number of replicates (n) and the statistical tests performed can be found in the figure legends. With the
exception of flow cytometry and bioluminescent imaging data, all analyses were performed using GraphPad PRISM software version
7 (GraphPad Software, Inc. La Jolla, CA). Throughout this work, significance was defined as p < 0.05. The P values for comparisons
between experimental groupswere calculated by use of an unpaired Student’s t test. Error is presented as standard error of themean
(SEM) unless otherwise noted.
For the RNaseq experiments, expression data was analyzed with ArrayStar (DNASTAR) and genes were considered differentially
expressed if they showed aR 4-fold change with 95% confidence as evaluated by Student’s t test with a false discovery rate (FDR)
correction applied for multiple t tests.
DATA AND SOFTWARE AVAILABILITY
The RNaseq results with LAC (+/ apicidin treatment) and the Dagr mutant were uploaded to the NCBI GEO database. Accession
information: https://www.ncbi.nlm.nih.gov/sra?term=SRP182661.e6 Cell Reports 27, 187–198.e1–e6, April 2, 2019
